Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30

Benzinga · 2d ago
Guggenheim analyst Michael Schmidt maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price target from $18 to $30.